Volume | 966,296 |
|
|||||
News | (1) | ||||||
Day High | 292.86 | Low High |
|||||
Day Low | 272.01 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Madrigal Pharmaceuticals Inc | MDGL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
274.48 | 272.01 | 292.86 | 283.23 | 270.37 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
25,219 | 966,296 | $ 284.30 | $ 274,716,387 | - | 119.7604 - 322.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:02 | 4 | $ 279.93 | USD |
Madrigal Pharmaceuticals (MDGL) Options Flow Summary
Madrigal Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.63B | 19.90M | - | 0 | -373.63M | -18.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Madrigal Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDGL Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 257.88 | 299.98 | 236.6201 | 261.86 | 1,305,540 | 22.19 | 8.60% |
1 Month | 232.52 | 299.98 | 214.00 | 252.87 | 704,502 | 47.55 | 20.45% |
3 Months | 235.74 | 299.98 | 168.2462 | 230.58 | 550,426 | 44.33 | 18.80% |
6 Months | 174.24 | 299.98 | 119.7604 | 198.22 | 496,219 | 105.83 | 60.74% |
1 Year | 252.00 | 322.67 | 119.7604 | 213.67 | 418,492 | 28.07 | 11.14% |
3 Years | 117.93 | 322.67 | 52.33 | 174.75 | 306,096 | 162.14 | 137.49% |
5 Years | 138.48 | 322.67 | 52.33 | 154.82 | 252,419 | 141.59 | 102.25% |
Madrigal Pharmaceuticals Description
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |